

Kentucky Department for Medicaid Services

Drug Review Options

The following chart lists the agenda items scheduled and the options submitted for review at the November 15, 2012 meeting of the Pharmacy and Therapeutics Advisory Committee.

Item	Options for Consideration
<u>New Products to Market:</u> <u>Dymista[®]</u>	Place this product non preferred with similar quantity limits in the PDL class titled Intranasal Rhinitis Agents.
<u>New Products to Market:</u> <u>Sklice[™]</u>	Place this product non preferred in the PDL class titled Dermatologics: Antiparasitics, Topical.
<u>New Products to Market:</u> <u>Neupro[®]</u>	Place this product non preferred in the PDL class titled Non-Ergot Dopamine Receptor Agonists.
<u>New Products to Market:</u> <u>Viokace[™]</u>	Place this product non preferred in the PDL class titled Pancreatic Enzymes.
<u>New Products to Market:</u> <u>Pertzye[™]</u>	Place this product non preferred in the PDL class titled Pancreatic Enzymes.
<u>New Products to Market:</u> <u>Myrbetriq[™]</u>	Place this product non preferred with similar quantity limits in the PDL class titled Urinary Tract Antispasmodics.
<u>New Products to Market:</u> <u>Tudorza[™] Pressair[™]</u>	Place this product non preferred with similar quantity limits in the PDL class titled COPD Agents.
<u>New Products to Market: Xtandi[®]</u>	Place this product non preferred with similar quantity limits in the PDL class titled Oral Oncology Agents.
<u>New Products to Market:</u> <u>Bosulif[®]</u>	Place this product non preferred with similar quantity limits in the PDL class titled Oral Oncology Agents.

Item	Options for Consideration
<p>Truvada[®] <u>Clinical</u> <u>Criteria</u></p>	<p>Initiation of Therapy: Truvada[®] should be approved initially if any ONE of the following is true:</p> <ul style="list-style-type: none"> • Treatment of HIV-1 infection; OR • Pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 if ALL of the following are true: <ul style="list-style-type: none"> ○ Prior Authorization request is coming from the prescriber; AND ○ High risk for contracting HIV-1, defined as: <ul style="list-style-type: none"> ▪ Male who has sex with men (MSM) and are at high risk for HIV-1 infection. ▪ Transgender woman, (e.g. male who has undergone a sex change), who has sex with men and are at high risk for HIV-1 infection. ▪ Male or female in a heterosexual HIV-1 serodiscordant relationship; AND ○ Negative HIV-1 test immediately prior to initiating Truvada[®]; AND ○ Risk-reduction and medication adherence counseling has been completed by prescriber. <p>**If the indication is pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1, Truvada[®] will only be approved for a duration of 3 months.</p> <p>Continuation of Therapy: Truvada[®] should be approved for continuation of therapy if any ONE of the following is true:</p> <ul style="list-style-type: none"> • Treatment of HIV-1 infection; OR • Pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 if ALL of the following are true: <ul style="list-style-type: none"> ○ Prior Authorization request is coming from the prescriber; AND ○ Substantial, ongoing, high risk for acquiring HIV infection as defined below: <ul style="list-style-type: none"> ▪ Male who has sex with men (MSM) and are at high risk for HIV-1 infection. ▪ Transgender woman, (e.g. male who has undergone a sex change), who has sex with men and are at high risk for HIV-1 infection. ▪ Male or female in a heterosexual HIV-1 serodiscordant relationship; AND ○ Negative HIV-1 test; AND ○ Risk-reduction and medication adherence counseling has been completed by prescriber no less frequently than every three months; AND ○ The patient has strictly adhered to the dosing schedule, as evident by pill counts. <p>**If the indication is pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1, Truvada[®] will only be approved for a duration of 3 months.</p>

Item	Options for Consideration
<u>Nucynta® ER Clinical Criteria</u>	<p>Nucynta® ER should be authorized for the following diagnoses:</p> <ul style="list-style-type: none"> • Pain after trial and failure of one preferred product; OR • Diabetic Peripheral Neuropathy after trial and failure of TWO of the following: <ul style="list-style-type: none"> ○ One SNRI; or ○ One anticonvulsant; or ○ One tricyclic antidepressant.
<u>First-Generation Antipsychotics</u>	<ol style="list-style-type: none"> 1. DMS to select preferred agent(s) based on economic evaluation; however, at least four unique chemical entities, at least one representing an agent from each of the potency groups, should be preferred. 2. Agents not selected as preferred will be considered non preferred and require prior authorization 3. Allow continuation of therapy for non preferred single source branded products via a 90 day look back. 4. For any new chemical entity in the First-Generation Antipsychotics class, require a PA until reviewed by the P&T Advisory Committee.
<u>Second-Generation Antipsychotics</u>	<ol style="list-style-type: none"> 1. DMS to select preferred agent(s) based on economic evaluation; however, at least five unique chemical entities should be preferred. 2. Require appropriate ICD-9 on all prescriptions for agents within this class. 3. Place quantity limits on all agents in the class. 4. Allow only two agents at a time unless switching agents due to therapeutic failure or the patient is refractory to dual therapy. 5. Allow continuation of therapy for non preferred single source branded products via a 90 day look back. 6. All products in the category should have a tier 1 copay regardless of preferred or non preferred status. 7. For any new chemical entity in the Second-Generation Antipsychotics class, require a PA until reviewed by the P&T Advisory Committee.

Item	Options for Consideration	
<p><u>Second-Generation Antipsychotics Clinical Criteria</u></p>	Preferred Second-Generation Antipsychotics will be allowed for the following diagnoses only.	
	Approvable ICD-9	Approvable Diagnosis Description
	Schizophrenic disorders	
	295.00	Simple Type Schizophrenia, Unspecified State Schizophrenia simplex
	295.01	Simple Type Schizophrenia, Subchronic State Schizophrenia simplex
	295.02	Simple Type Schizophrenia, Chronic State Schizophrenia simplex
	295.03	Simple Type Schizophrenia, Subchronic State With Acute Exacerbation Schizophrenia simplex
	295.04	Simple Type Schizophrenia, Chronic State With Acute Exacerbation Schizophrenia simplex
	295.05	Simple Type Schizophrenia, In Remission Schizophrenia simplex
	295.10	Disorganized Type Schizophrenia, Unspecified State Hebephrenia; Hebephrenic type schizophrenia
	295.11	Disorganized Type Schizophrenia, Subchronic State Hebephrenia; Hebephrenic type schizophrenia
	295.12	Disorganized Type Schizophrenia, Chronic State Hebephrenia; Hebephrenic type schizophrenia
	295.13	Disorganized Type Schizophrenia, Subchronic State With Acute Exacerbation Hebephrenia; Hebephrenic type schizophrenia
	295.14	Disorganized Type Schizophrenia, Chronic State With Acute Exacerbation Hebephrenia; Hebephrenic type schizophrenia
	295.15	Disorganized Type Schizophrenia, In Remission Hebephrenia; Hebephrenic type schizophrenia
	295.20	Catatonic Type Schizophrenia, Unspecified State Catatonic (schizophrenia): agitation, excitation, excited type, stupor, withdrawn type; Schizophrenic: catalepsy, catatonia, flexibilitas cerea
	295.21	Catatonic Type Schizophrenia, Subchronic State Catatonic (schizophrenia): agitation, excitation, excited type, stupor, withdrawn type; Schizophrenic: catalepsy, catatonia, flexibilitas cerea
295.22	Catatonic Type Schizophrenia, Chronic State Catatonic (schizophrenia): agitation, excitation, excited type, stupor, withdrawn type; Schizophrenic: catalepsy, catatonia, flexibilitas cerea	

295.23	Catatonic Type Schizophrenia, Subchronic State With Acute Exacerbation Catatonic (schizophrenia): agitation, excitation, excited type, stupor, withdrawn type; Schizophrenic: catalepsy, catatonia, flexibilitas cerea
295.24	Catatonic Type Schizophrenia, Chronic State With Acute Exacerbation Catatonic (schizophrenia): agitation, excitation, excited type, stupor, withdrawn type; Schizophrenic: catalepsy, catatonia, flexibilitas cerea
295.25	Catatonic Type Schizophrenia, In Remission Catatonic (schizophrenia): agitation, excitation, excited type, stupor, withdrawn type; Schizophrenic: catalepsy, catatonia, flexibilitas cerea
295.30	Paranoid Type Schizophrenia, Unspecified State Paraphrenic schizophrenia
295.31	Paranoid Type Schizophrenia, Subchronic State Paraphrenic schizophrenia
295.32	Paranoid Type Schizophrenia, Chronic State Paraphrenic schizophrenia
295.33	Paranoid Type Schizophrenia, Subchronic State With Acute Exacerbation Paraphrenic schizophrenia
295.34	Paranoid Type Schizophrenia, Chronic State With Acute Exacerbation Paraphrenic schizophrenia
295.35	Paranoid Type Schizophrenia, In Remission Paraphrenic schizophrenia
295.40	Schizophreniform Disorder, Unspecified State Oneirophrenia; Schizophreniform: attack, disorder, psychosis confusional type
295.41	Schizophreniform Disorder, Subchronic State Oneirophrenia; Schizophreniform: attack, disorder, psychosis confusional type
295.42	Schizophreniform Disorder, Chronic State Oneirophrenia; Schizophreniform: attack, disorder, psychosis confusional type
295.43	Schizophreniform Disorder, Subchronic State With Acute Exacerbation Oneirophrenia; Schizophreniform: attack, disorder, psychosis confusional type
295.44	Schizophreniform Disorder, Chronic State With Acute Exacerbation Oneirophrenia; Schizophreniform: attack, disorder, psychosis confusional type
295.45	Schizophreniform Disorder, In Remission Oneirophrenia; Schizophreniform: attack, disorder, psychosis confusional type

295.50	Latent Schizophrenia, Unspecified State Latent schizophrenic reaction; Schizophrenia: borderline, incipient, prepsychotic, prodromal, pseudoneurotic, pseudopsychopathic
295.51	Latent Schizophrenia, Subchronic State Latent schizophrenic reaction; Schizophrenia: borderline, incipient, prepsychotic, prodromal, pseudoneurotic, pseudopsychopathic
295.52	Latent Schizophrenia, Chronic State Latent schizophrenic reaction; Schizophrenia: borderline, incipient, prepsychotic, prodromal, pseudoneurotic, pseudopsychopathic
295.53	Latent Schizophrenia, Subchronic State With Acute Exacerbation Latent schizophrenic reaction; Schizophrenia: borderline, incipient, prepsychotic, prodromal, pseudoneurotic, pseudopsychopathic
295.54	Latent Schizophrenia, Chronic State With Acute Exacerbation Latent schizophrenic reaction; Schizophrenia: borderline, incipient, prepsychotic, prodromal, pseudoneurotic, pseudopsychopathic
295.55	Latent Schizophrenia, In Remission Latent schizophrenic reaction; Schizophrenia: borderline, incipient, prepsychotic, prodromal, pseudoneurotic, pseudopsychopathic
295.60	Residual Schizophrenia, Unspecified State Chronic undifferentiated schizophrenia; Restzustand (schizophrenic); Schizophrenic residual state
295.61	Residual Schizophrenia, Subchronic State Chronic undifferentiated schizophrenia; Restzustand (schizophrenic); Schizophrenic residual state
295.62	Residual Schizophrenia, Chronic State Chronic undifferentiated schizophrenia; Restzustand (schizophrenic); Schizophrenic residual state
295.63	Residual Schizophrenia, Subchronic State With Acute Exacerbation Chronic undifferentiated schizophrenia; Restzustand (schizophrenic); Schizophrenic residual state
295.64	Residual Schizophrenia, Chronic State With Acute Exacerbation Chronic undifferentiated schizophrenia; Restzustand (schizophrenic); Schizophrenic residual state
295.65	Residual Schizophrenia, In Remission Chronic undifferentiated schizophrenia; Restzustand (schizophrenic); Schizophrenic residual state
295.70	Schizoaffective Disorder, Unspecified State Cyclic schizophrenia; Mixed schizophrenic and affective psychosis; Schizo-affective psychosis; Schizophreniform psychosis, affective type

295.71	Schizoaffective Disorder, Subchronic State Cyclic schizophrenia; Mixed schizophrenic and affective psychosis; Schizo-affective psychosis; Schizophreniform psychosis, affective type
295.72	Schizoaffective Disorder, Chronic State Cyclic schizophrenia; Mixed schizophrenic and affective psychosis; Schizo-affective psychosis; Schizophreniform psychosis, affective type
295.73	Schizoaffective Disorder, Subchronic State With Acute Exacerbation Cyclic schizophrenia; Mixed schizophrenic and affective psychosis; Schizo-affective psychosis; Schizophreniform psychosis, affective type
295.74	Schizoaffective Disorder, Chronic State With Acute Exacerbation Cyclic schizophrenia; Mixed schizophrenic and affective psychosis; Schizo-affective psychosis; Schizophreniform psychosis, affective type
295.75	Schizoaffective Disorder, In Remission Cyclic schizophrenia; Mixed schizophrenic and affective psychosis; Schizo-affective psychosis; Schizophreniform psychosis, affective type
295.80	Other Specified Types Of Schizophrenia, Unspecified State Acute (undifferentiated) schizophrenia; Atypical schizophrenia; Cenesthopathic schizophrenia
295.81	Other Specified Types Of Schizophrenia, Subchronic State Acute (undifferentiated) schizophrenia; Atypical schizophrenia; Cenesthopathic schizophrenia
295.82	Other Specified Types Of Schizophrenia, Chronic State Acute (undifferentiated) schizophrenia; Atypical schizophrenia; Cenesthopathic schizophrenia
295.83	Other Specified Types Of Schizophrenia, Subchronic State With Acute Exacerbation Acute (undifferentiated) schizophrenia; Atypical schizophrenia; Cenesthopathic schizophrenia
295.84	Other Specified Types Of Schizophrenia, Chronic State With Acute Exacerbation Acute (undifferentiated) schizophrenia; Atypical schizophrenia; Cenesthopathic schizophrenia
295.85	Other Specified Types Of Schizophrenia, In Remission Acute (undifferentiated) schizophrenia; Atypical schizophrenia; Cenesthopathic schizophrenia
295.90	Unspecified Schizophrenia, Unspecified State Schizophrenia: NOS, mixed NOS, undifferentiated NOS; Schizophrenic reaction NOS; Schizophreniform psychosis NOS

295.91	Unspecified Schizophrenia, Subchronic State Schizophrenia: NOS, mixed NOS, undifferentiated NOS; Schizophrenic reaction NOS; Schizophreniform psychosis NOS
295.92	Unspecified Schizophrenia, Chronic State Schizophrenia: NOS, mixed NOS, undifferentiated NOS; Schizophrenic reaction NOS; Schizophreniform psychosis NOS
295.93	Unspecified Schizophrenia, Subchronic State With Acute Exacerbation Schizophrenia: NOS, mixed NOS, undifferentiated NOS; Schizophrenic reaction NOS; Schizophreniform psychosis NOS
295.94	Unspecified Schizophrenia, Chronic State With Acute Exacerbation Schizophrenia: NOS, mixed NOS, undifferentiated NOS; Schizophrenic reaction NOS; Schizophreniform psychosis NOS
295.95	Unspecified Schizophrenia, In Remission Schizophrenia: NOS, mixed NOS, undifferentiated NOS; Schizophrenic reaction NOS; Schizophreniform psychosis NOS
Episodic Mood Disorders	
296.00	Bipolar I Disorder, Single Manic Episode, Unspecified Degree {Hypomania (mild) NOS} {Hypomanic psychosis} {Mania (monopolar) NOS} {Manic-depressive psychosis or reaction: hypomanic, manic} single episode or unspecified
296.01	Bipolar I Disorder, Single Manic Episode, Mild Degree {Hypomania (mild) NOS} {Hypomanic psychosis} {Mania (monopolar) NOS} {Manic-depressive psychosis or reaction: hypomanic, manic} single episode or unspecified
296.02	Bipolar I Disorder, Single Manic Episode, Moderate Degree {Hypomania (mild) NOS} {Hypomanic psychosis} {Mania (monopolar) NOS} {Manic-depressive psychosis or reaction: hypomanic, manic} single episode or unspecified
296.03	Bipolar I Disorder, Single Manic Episode Severe Degree, Without Mention Of Psychotic Behavior {Hypomania (mild) NOS} {Hypomanic psychosis} {Mania (monopolar) NOS} {Manic-depressive psychosis or reaction: hypomanic, manic} single episode or unspecified
296.04	Bipolar I Disorder, Single Manic Episode, Severe Degree, Specified As With Psychotic Behavior {Hypomania (mild) NOS} {Hypomanic psychosis} {Mania (monopolar) NOS} {Manic-depressive psychosis or reaction: hypomanic, manic} single episode or unspecified

296.05	Bipolar I Disorder, Single Manic Episode, In Partial Or Unspecified Remission {Hypomania (mild) NOS} {Hypomanic psychosis} {Mania (monopolar) NOS} {Manic-depressive psychosis or reaction: hypomanic, manic} single episode or unspecified
296.06	Bipolar I Disorder, Single Manic Episode, In Full Remission {Hypomania (mild) NOS} {Hypomanic psychosis} {Mania (monopolar) NOS} {Manic-depressive psychosis or reaction: hypomanic, manic} single episode or unspecified
296.10	Manic Disorder, Recurrent Episode, Unspecified Degree Any condition classifiable to 296.0, stated to be recurrent
296.11	Manic Disorder, Recurrent Episode, Mild Degree Any condition classifiable to 296.0, stated to be recurrent
296.12	Manic Disorder, Recurrent Episode, Moderate Degree Any condition classifiable to 296.0, stated to be recurrent
296.13	Manic Disorder, Recurrent Episode, Severe Degree, Without Mention Of Psychotic Behavior Any condition classifiable to 296.0, stated to be recurrent
296.14	Manic Disorder, Recurrent Episode, Severe Degree, Specified As With Psychotic Behavior Any condition classifiable to 296.0, stated to be recurrent
296.15	Manic Disorder, Recurrent Episode, In Partial Or Unspecified Remission Any condition classifiable to 296.0, stated to be recurrent
296.16	Manic Disorder, Recurrent Episode, In Full Remission Any condition classifiable to 296.0, stated to be recurrent
296.40	Bipolar I Disorder, Most Recent Episode (Or Current) Manic, Unspecified Degree Bipolar disorder, now manic; Manic-depressive psychosis, circular type but currently manic
296.41	Bipolar I Disorder, Most Recent Episode (Or Current) Manic, Mild Degree Bipolar disorder, now manic; Manic-depressive psychosis, circular type but currently manic
296.42	Bipolar I Disorder, Most Recent Episode (Or Current) Manic, Moderate Degree Bipolar disorder, now manic; Manic-depressive psychosis, circular type but currently manic
296.43	Bipolar I Disorder, Most Recent Episode (Or Current) Manic, Severe Degree, Without Mention Of Psychotic Behavior Bipolar disorder, now manic Manic-depressive psychosis, circular type but currently manic
296.44	Bipolar I Disorder, Most Recent Episode (Or Current) Manic, Severe Degree, Specified As With Psychotic Behavior Bipolar disorder, now manic; Manic-depressive psychosis, circular type but currently manic

296.45	Bipolar I Disorder, Most Recent Episode (Or Current) Manic, In Partial Or Unspecified Remission Bipolar disorder, now manic; Manic-depressive psychosis, circular type but currently manic
296.46	Bipolar I Disorder, Most Recent Episode (Or Current) Manic, In Full Remission Bipolar disorder, now manic Manic-depressive psychosis, circular type but currently manic
296.50	Bipolar I Disorder, Most Recent Episode (Or Current) Depressed, Unspecified Degree Bipolar disorder, now depressed; Manic-depressive psychosis, circular type but currently depressed
296.51	Bipolar I Disorder, Most Recent Episode (Or Current) Depressed, Mild Degree Bipolar disorder, now depressed; Manic-depressive psychosis, circular type but currently depressed
296.52	Bipolar I Disorder, Most Recent Episode (Or Current) Depressed, Moderate Degree Bipolar disorder, now depressed; Manic-depressive psychosis, circular type but currently depressed
296.53	Bipolar I Disorder, Most Recent Episode (Or Current) Depressed, Severe Degree, Without Mention Of Psychotic Behavior Bipolar disorder, now depressed; Manic-depressive psychosis, circular type but currently depressed
296.54	Bipolar I Disorder, Most Recent Episode (Or Current) Depressed, Severe Degree, Specified As With Psychotic Behavior Bipolar disorder, now depressed; Manic-depressive psychosis, circular type but currently depressed
296.55	Bipolar I Disorder, Most Recent Episode (Or Current) Depressed, In Partial Or Unspecified Remission Bipolar disorder, now depressed; Manic-depressive psychosis, circular type but currently depressed
296.56	Bipolar I Disorder, Most Recent Episode (Or Current) Depressed, In Remission Bipolar disorder, now depressed; Manic-depressive psychosis, circular type but currently depressed
296.60	Bipolar I Disorder, Most Recent Episode (Or Current) Mixed, Unspecified Degree Manic-depressive psychosis, circular type, mixed
296.61	Bipolar I Disorder, Most Recent Episode (Or Current) Mixed, Mild Degree Manic-depressive psychosis, circular type, mixed
296.62	Bipolar I Disorder, Most Recent Episode (Or Current) Mixed, Moderate Degree Manic-depressive psychosis, circular type, mixed

296.63	Bipolar I Disorder, Most Recent Episode (Or Current) Mixed, Severe Degree, Without Mention Of Psychotic Behavior Manic-depressive psychosis, circular type, mixed
296.64	Bipolar I Disorder, Most Recent Episode (Or Current) Mixed, Severe Degree, Specified As With Psychotic Behavior Manic-depressive psychosis, circular type, mixed
296.65	Bipolar I Disorder, Most Recent Episode (Or Current) Mixed, In Partial Or Unspecified Remission Manic-depressive psychosis, circular type, mixed
296.66	Bipolar I Disorder, Most Recent Episode (Or Current) Mixed, In Full Remission Manic-depressive psychosis, circular type, mixed
296.7	Bipolar I disorder, most recent episode 9or current0 unspecified
296.80	Bipolar Disorder, Unspecified Bipolar disorder NOS; Manic-depressive: reaction NOS, syndrome NOS
296.81	Atypical Manic Disorder
296.82	Atypical Depressive Disorder
296.89	Other Manic-depressive Psychosis Bipolar II Disorder; Manic-depressive psychosis, mixed type
296.90	Unspecified Episodic Mood Disorder Affective psychosis NOS; Melancholia NOS; Mood disorder NOS
296.99	Other Specified Episodic Mood Disorder Mood swings: brief compensatory, rebound
Delusional disorders	
297.0	Paranoid State, Simple
297.1	Delusional Disorder Chronic paranoid psychosis; Sander's disease; Systematized delusions
297.2	Paraphrenia Involuntal paranoid state; Late paraphrenia; Paraphrenia (involuntal)
297.3	Shared Psychotic Disorder Folie a deux; Induced psychosis or paranoid disorder
297.8	Other Specified Paranoid States Paranoia querulans; Sensitiver Beziehungswahn
297.9	Unspecified Paranoid State Paranoid: disorder NOS, psychosis NOS, reaction NOS, state NOS
298.0	Depressive Type Psychosis Psychogenic depressive psychosis; Psychotic reactive depression; Reactive depressive psychosis
298.1	Excitative Type Psychosis Acute hysterical psychosis; Psychogenic excitation; Reactive excitation

298.2	Reactive Confusion Psychogenic confusion; Psychogenic twilight state
298.3	Acute Paranoid Reaction Acute psychogenic paranoid psychosis; Bouffee delirante
298.4	Psychogenic Paranoid Psychosis Protracted reactive paranoid psychosis
298.8	Other And Unspecified Reactive Psychosis Brief psychotic disorder; Brief reactive psychosis NOS; Hysterical psychosis; Psychogenic psychosis NOS; Psychogenic stupor
298.9	Unspecified Psychosis Atypical psychosis; Psychosis NOS; Psychotic disorder NOS
301.20	Schizoid Personality Disorder, Unspecified
301.21	Introverted Personality
301.22	Schizotypal Personality Disorder
Autism	
299.00	Autistic Disorder Childhood autism; Infantile psychosis; Kanner's syndrome
299.01	Autistic Disorder, Residual State Childhood autism; Infantile psychosis; Kanner's syndrome
299.10	Childhood Disintegrative Disorder, Current Or Active State Heller's syndrome
299.11	Childhood Disintegrative Disorder, Residual State Heller's syndrome
299.80	Other Specified Pervasive Developmental Disorders, Current Or Active State Atypical childhood psychosis; Borderline psychosis of childhood
299.81	Other Specified Pervasive Developmental Disorders, Residual State Atypical childhood psychosis; Borderline psychosis of childhood
299.90	Unspecified Pervasive developmental disorder, Current Or Active State Child psychosis NOS; Schizophrenia, childhood type NOS; Schizophrenic syndrome of childhood NOS
299.91	Unspecified Pervasive developmental disorder, Residual State Child psychosis NOS; Schizophrenia, childhood type NOS; Schizophrenic syndrome of childhood NOS
Dementias	
290.0	Senile Dementia, Uncomplicated Senile dementia: NOS, simple type
290.10	Presenile Dementia, Uncomplicated Brain syndrome with presenile brain disease; Dementia in: Alzheimer's disease, Jakob-Creutzfeldt disease, Pick's disease of the brain; Presenile dementia: NOS, simple type

290.11	Presenile Dementia, With Delirium Brain syndrome with presenile brain disease; Dementia in: Alzheimer's disease, Jakob-Creutzfeldt disease, Pick's disease of the brain; Presenile dementia with acute confusional state
290.12	Presenile Dementia, With Delusional Features Brain syndrome with presenile brain disease; Dementia in: Alzheimer's disease, Jakob-Creutzfeldt disease, Pick's disease of the brain; Presenile dementia, paranoid type
290.13	Presenile Dementia, With Depressive Features Brain syndrome with presenile brain disease; Dementia in: Alzheimer's disease, Jakob-Creutzfeldt disease, Pick's disease of the brain; Presenile dementia, depressed type
290.20	Senile Dementia With Delusional Features Senile dementia, paranoid type; Senile psychosis NOS
290.21	Senile Dementia With Depressive Features
290.3	Senile Dementia With Delirium Senile dementia with acute confusional state
290.40	Vascular Dementia, Uncomplicated Arteriosclerotic dementia: NOS, simple type; Multi-infarct dementia or psychosis
290.41	Vascular Dementia, With Delirium Arteriosclerotic dementia with acute confusional state; Multi-infarct dementia or psychosis
290.42	Vascular Dementia, With Delusions Arteriosclerotic dementia, paranoid type; Multi-infarct dementia or psychosis
290.43	Vascular Dementia, With Depressed Mood Arteriosclerotic dementia, depressed type; Multi-infarct dementia or psychosis
290.8	Other Specified Senile Psychotic Conditions Presbyophrenic psychosis
290.9	Unspecified Senile Psychotic Condition
Dissociative, Conversion And Factitious Disorders	
300.10	Hysteria, Unspecified
300.11	Conversion Disorder Astasia-abasia, hysterical; Conversion hysteria or reaction; Hysterical: blindness, deafness, paralysis
300.12	Dissociative Amnesia Hysterical amnesia
300.13	Dissociative Fugue Hysterical fugue
300.14	Dissociative Identity Disorder
300.15	Dissociative Disorder Or Reaction, Unspecified
300.16	Factitious Disorder With Predominantly Psychological Signs And Symptoms Compensation neurosis; Ganser's syndrome, hysterical

300.19	Other And Unspecified Factitious Illness Factitious Disorder (with combined psychological and physical signs and symptoms) (with predominantly physical signs and symptoms) NOS
Other	
292.11	Drug-Induced Psychotic Disorder With Delusions Paranoid state induced by drugs
292.12	Drug-Induced Psychotic Disorder With Hallucinations Hallucinatory state induced by drugs
293.81	Psychotic Disorder With Delusions In Conditions Classified Elsewhere Transient organic psychotic condition, paranoid type
293.82	Psychotic Disorder With Hallucinations In Conditions Classified Elsewhere Transient organic psychotic condition, hallucinatory type
307.20	Tic Disorder, Unspecified Tic disorder NOS
307.21	Transient Tic Disorder
307.22	Chronic Motor Or Vocal Tic Disorder
307.23	Tourette's Disorder Motor-verbal tic disorder
313.81	Oppositional Defiant Disorder Of Childhood Or Adolescence
333.4	Huntington's Chorea

*Non preferred Second-Generation Antipsychotics will be approved after a 2-week trial of ONE preferred Second-Generation Antipsychotic at an appropriate dose. If Invega® is selected as non preferred, approval will be granted if one of the following is true:

- Trial and failure of risperidone; OR
- Patient has hepatic impairment evident by elevated liver enzymes or a diagnosis suggestive of hepatic impairment.

**For a diagnosis not specifically mentioned above, a Second-Generation Antipsychotic may be approved if the prescriber can provide documented clinical evidence (peer reviewed literature or multiple case studies) supporting the use of the requested medication for the requested indication.

Major Depressive Disorder (MDD) Criteria:

Second-Generation Antipsychotics will be approved for MDD as adjunct therapy ONLY. Second-Generation Antipsychotics will be approved if any ONE of the following is true:

- An adequate trial (4 weeks) of at least one agent in two of the following classes of antidepressants (unless contraindicated or intolerant to):
 - Selective Serotonins Reuptake Inhibitor (SSRIs)
 - Serotonin-Norepinephrine Reuptake Inhibitor (SNRIs)
 - New Generation Antidepressants
 - Tricyclic antidepressants (TCAs); OR
- A diagnosis of Major Depressive Disorder (MDD) with psychotic features.

Multiple Agents Criteria:

Patients who are on more than 2 Second-Generation Antipsychotic agents will require PA. Approval will be granted for the following reasons:

- A maximum of 2 months to allow patients to taper to dual therapy.
- Additional agents may be added to existing dual therapy after a 2-week trial at the maximum tolerated dose of each agent.

Proposed Quantity Limits:

Drug	Strength	Per Day Count
Abilify [®]	All Strengths	1 per day (30 mg per day max)
Abilify Discmelt [®]	All Strengths	2 per day (30 mg per day max)
Abilify [®] oral solution	1mg/mL	30 mL per day (30 mg per day max)
Clozaril [®] / clozapine	25 mg	3 per day (900 mg per day max)
	50 mg	3 per day (900 mg per day max)
	100 mg	9 per day (900 mg per day max)
	200 mg	4 per day (900 mg per day max)
Fanapt [™]	All Strengths	2 per day (24 mg per day max)
FazaClo ODT [®] / clozapine	12.5 mg	3 per day (900 mg per day max)
	25 mg	3 per day (900 mg per day max)
	100 mg	9 per day (900 mg per day max)
	150 mg	6 per day (900 mg per day max)
	200 mg	4 per day (900 mg per day max)
Geodon [®] / ziprasidone	All Strengths	2 per day (160 mg per day max)
Invega [®]	1.5 mg	1 per day (12 mg per day max)
	3 mg	1 per day (12 mg per day max)
	6 mg	2 per day (12 mg per day max)
	9 mg	1 per day (12 mg per day max)
Latuda [®]	20 mg	1 per day (160 mg per day max)
	40 mg	1 per day (160 mg per day max)
	80 mg	2 per day (160 mg per day max)
	120 mg	1 per day (160 mg per day max)
Risperdal [®] / risperidone	All Strengths	2 per day (8 mg per day max)
Risperdal [®] / risperidone oral solution	1 mg/mL	8 mL per day (8 mg per day max)
Saphris [®]	All Strengths	2 per day (20 mg per day max)
Seroquel [®] / quetiapine	25 mg	3 per day (800 mg per day max)
	50 mg	3 per day (800 mg per day max)
	100 mg	3 per day (800 mg per day max)
	200 mg	3 per day (800 mg per day max)
	300 mg	2 per day (800 mg per day max)
	400 mg	2 per day (800 mg per day max)
Seroquel XR [®]	50 mg	2 per day (800 mg per day max)
	150 mg	1 per day (800 mg per day max)
	200 mg	1 per day (800 mg per day max)
	300 mg	2 per day (800 mg per day max)
	400 mg	2 per day (800 mg per day max)
Zyprexa [®] / Zyprexa Zydis [®] / olanzapine	All Strengths	1 per day

Item	Options for Consideration																												
<u>Injectable Antipsychotics</u>	<ol style="list-style-type: none"> 1. DMS to select preferred agent(s) based on economic evaluation. Generic formulations of first generation injectable antipsychotics should be preferred. Additionally, two unique second generation injectable antipsychotics, one of which should have a duration of action of 2 weeks or longer, should be preferred. 2. Require appropriate ICD-9 on all prescriptions for agents within this class. 3. Allow only two agents at a time unless switching agents due to therapeutic failure or the patient is refractory to dual therapy. 4. Allow continuation of therapy for non preferred single source branded products via a 90 day look back. 5. All products in the category should have a tier 1 copay regardless of preferred or non preferred status. 6. For any new chemical entity in the Injectable Antipsychotics class, require a PA until reviewed by the P&T Advisory Committee. 																												
<u>Injectable Antipsychotics Clinical Criteria</u>	<p>Preferred Injectable Antipsychotics will be allowed for the following diagnoses only.</p> <table border="1" data-bbox="444 762 1554 1892"> <thead> <tr> <th data-bbox="444 762 725 800">Approvable ICD-9</th> <th data-bbox="725 762 1554 800">Approvable Diagnosis Description</th> </tr> </thead> <tbody> <tr> <td colspan="2" data-bbox="444 800 1554 833" style="text-align: center;">Schizophrenic disorders</td> </tr> <tr> <td data-bbox="444 833 725 900">295.00</td> <td data-bbox="725 833 1554 900">Simple Type Schizophrenia, Unspecified State Schizophrenia simplex</td> </tr> <tr> <td data-bbox="444 900 725 968">295.01</td> <td data-bbox="725 900 1554 968">Simple Type Schizophrenia, Subchronic State Schizophrenia simplex</td> </tr> <tr> <td data-bbox="444 968 725 1035">295.02</td> <td data-bbox="725 968 1554 1035">Simple Type Schizophrenia, Chronic State Schizophrenia simplex</td> </tr> <tr> <td data-bbox="444 1035 725 1140">295.03</td> <td data-bbox="725 1035 1554 1140">Simple Type Schizophrenia, Subchronic State With Acute Exacerbation Schizophrenia simplex</td> </tr> <tr> <td data-bbox="444 1140 725 1245">295.04</td> <td data-bbox="725 1140 1554 1245">Simple Type Schizophrenia, Chronic State With Acute Exacerbation Schizophrenia simplex</td> </tr> <tr> <td data-bbox="444 1245 725 1312">295.05</td> <td data-bbox="725 1245 1554 1312">Simple Type Schizophrenia, In Remission Schizophrenia simplex</td> </tr> <tr> <td data-bbox="444 1312 725 1379">295.10</td> <td data-bbox="725 1312 1554 1379">Disorganized Type Schizophrenia, Unspecified State Hebephrenia; Hebephrenic type schizophrenia</td> </tr> <tr> <td data-bbox="444 1379 725 1446">295.11</td> <td data-bbox="725 1379 1554 1446">Disorganized Type Schizophrenia, Subchronic State Hebephrenia; Hebephrenic type schizophrenia</td> </tr> <tr> <td data-bbox="444 1446 725 1514">295.12</td> <td data-bbox="725 1446 1554 1514">Disorganized Type Schizophrenia, Chronic State Hebephrenia; Hebephrenic type schizophrenia</td> </tr> <tr> <td data-bbox="444 1514 725 1619">295.13</td> <td data-bbox="725 1514 1554 1619">Disorganized Type Schizophrenia, Subchronic State With Acute Exacerbation Hebephrenia; Hebephrenic type schizophrenia</td> </tr> <tr> <td data-bbox="444 1619 725 1724">295.14</td> <td data-bbox="725 1619 1554 1724">Disorganized Type Schizophrenia, Chronic State With Acute Exacerbation Hebephrenia; Hebephrenic type schizophrenia</td> </tr> <tr> <td data-bbox="444 1724 725 1892">295.15</td> <td data-bbox="725 1724 1554 1892">Disorganized Type Schizophrenia, In Remission Hebephrenia; Hebephrenic type schizophrenia</td> </tr> </tbody> </table>	Approvable ICD-9	Approvable Diagnosis Description	Schizophrenic disorders		295.00	Simple Type Schizophrenia, Unspecified State Schizophrenia simplex	295.01	Simple Type Schizophrenia, Subchronic State Schizophrenia simplex	295.02	Simple Type Schizophrenia, Chronic State Schizophrenia simplex	295.03	Simple Type Schizophrenia, Subchronic State With Acute Exacerbation Schizophrenia simplex	295.04	Simple Type Schizophrenia, Chronic State With Acute Exacerbation Schizophrenia simplex	295.05	Simple Type Schizophrenia, In Remission Schizophrenia simplex	295.10	Disorganized Type Schizophrenia, Unspecified State Hebephrenia; Hebephrenic type schizophrenia	295.11	Disorganized Type Schizophrenia, Subchronic State Hebephrenia; Hebephrenic type schizophrenia	295.12	Disorganized Type Schizophrenia, Chronic State Hebephrenia; Hebephrenic type schizophrenia	295.13	Disorganized Type Schizophrenia, Subchronic State With Acute Exacerbation Hebephrenia; Hebephrenic type schizophrenia	295.14	Disorganized Type Schizophrenia, Chronic State With Acute Exacerbation Hebephrenia; Hebephrenic type schizophrenia	295.15	Disorganized Type Schizophrenia, In Remission Hebephrenia; Hebephrenic type schizophrenia
Approvable ICD-9	Approvable Diagnosis Description																												
Schizophrenic disorders																													
295.00	Simple Type Schizophrenia, Unspecified State Schizophrenia simplex																												
295.01	Simple Type Schizophrenia, Subchronic State Schizophrenia simplex																												
295.02	Simple Type Schizophrenia, Chronic State Schizophrenia simplex																												
295.03	Simple Type Schizophrenia, Subchronic State With Acute Exacerbation Schizophrenia simplex																												
295.04	Simple Type Schizophrenia, Chronic State With Acute Exacerbation Schizophrenia simplex																												
295.05	Simple Type Schizophrenia, In Remission Schizophrenia simplex																												
295.10	Disorganized Type Schizophrenia, Unspecified State Hebephrenia; Hebephrenic type schizophrenia																												
295.11	Disorganized Type Schizophrenia, Subchronic State Hebephrenia; Hebephrenic type schizophrenia																												
295.12	Disorganized Type Schizophrenia, Chronic State Hebephrenia; Hebephrenic type schizophrenia																												
295.13	Disorganized Type Schizophrenia, Subchronic State With Acute Exacerbation Hebephrenia; Hebephrenic type schizophrenia																												
295.14	Disorganized Type Schizophrenia, Chronic State With Acute Exacerbation Hebephrenia; Hebephrenic type schizophrenia																												
295.15	Disorganized Type Schizophrenia, In Remission Hebephrenia; Hebephrenic type schizophrenia																												

295.20	Catatonic Type Schizophrenia, Unspecified State Catatonic (schizophrenia): agitation, excitation, excited type, stupor, withdrawn type; Schizophrenic: catalepsy, catatonia, flexibilitas cerea
295.21	Catatonic Type Schizophrenia, Subchronic State Catatonic (schizophrenia): agitation, excitation, excited type, stupor, withdrawn type; Schizophrenic: catalepsy, catatonia, flexibilitas cerea
295.22	Catatonic Type Schizophrenia, Chronic State Catatonic (schizophrenia): agitation, excitation, excited type, stupor, withdrawn type; Schizophrenic: catalepsy, catatonia, flexibilitas cerea
295.23	Catatonic Type Schizophrenia, Subchronic State With Acute Exacerbation Catatonic (schizophrenia): agitation, excitation, excited type, stupor, withdrawn type; Schizophrenic: catalepsy, catatonia, flexibilitas cerea
295.24	Catatonic Type Schizophrenia, Chronic State With Acute Exacerbation Catatonic (schizophrenia): agitation, excitation, excited type, stupor, withdrawn type; Schizophrenic: catalepsy, catatonia, flexibilitas cerea
295.25	Catatonic Type Schizophrenia, In Remission Catatonic (schizophrenia): agitation, excitation, excited type, stupor, withdrawn type; Schizophrenic: catalepsy, catatonia, flexibilitas cerea
295.30	Paranoid Type Schizophrenia, Unspecified State Paraphrenic schizophrenia
295.31	Paranoid Type Schizophrenia, Subchronic State Paraphrenic schizophrenia
295.32	Paranoid Type Schizophrenia, Chronic State Paraphrenic schizophrenia
295.33	Paranoid Type Schizophrenia, Subchronic State With Acute Exacerbation Paraphrenic schizophrenia
295.34	Paranoid Type Schizophrenia, Chronic State With Acute Exacerbation Paraphrenic schizophrenia
295.35	Paranoid Type Schizophrenia, In Remission Paraphrenic schizophrenia
295.40	Schizophreniform Disorder, Unspecified State Oneirophrenia; Schizophreniform: attack, disorder, psychosis confusional type
295.41	Schizophreniform Disorder, Subchronic State Oneirophrenia; Schizophreniform: attack, disorder, psychosis confusional type
295.42	Schizophreniform Disorder, Chronic State Oneirophrenia; Schizophreniform: attack, disorder, psychosis confusional type

295.43	Schizophreniform Disorder, Subchronic State With Acute Exacerbation Oneirophrenia; Schizophreniform: attack, disorder, psychosis confusional type
295.44	Schizophreniform Disorder, Chronic State With Acute Exacerbation Oneirophrenia; Schizophreniform: attack, disorder, psychosis confusional type
295.45	Schizophreniform Disorder, In Remission Oneirophrenia; Schizophreniform: attack, disorder, psychosis confusional type
295.50	Latent Schizophrenia, Unspecified State Latent schizophrenic reaction; Schizophrenia: borderline, incipient, prepsychotic, prodromal, pseudoneurotic, pseudopsychopathic
295.51	Latent Schizophrenia, Subchronic State Latent schizophrenic reaction; Schizophrenia: borderline, incipient, prepsychotic, prodromal, pseudoneurotic, pseudopsychopathic
295.52	Latent Schizophrenia, Chronic State Latent schizophrenic reaction; Schizophrenia: borderline, incipient, prepsychotic, prodromal, pseudoneurotic, pseudopsychopathic
295.53	Latent Schizophrenia, Subchronic State With Acute Exacerbation Latent schizophrenic reaction; Schizophrenia: borderline, incipient, prepsychotic, prodromal, pseudoneurotic, pseudopsychopathic
295.54	Latent Schizophrenia, Chronic State With Acute Exacerbation Latent schizophrenic reaction; Schizophrenia: borderline, incipient, prepsychotic, prodromal, pseudoneurotic, pseudopsychopathic
295.55	Latent Schizophrenia, In Remission Latent schizophrenic reaction; Schizophrenia: borderline, incipient, prepsychotic, prodromal, pseudoneurotic, pseudopsychopathic
295.60	Residual Schizophrenia, Unspecified State Chronic undifferentiated schizophrenia; Restzustand (schizophrenic); Schizophrenic residual state
295.61	Residual Schizophrenia, Subchronic State Chronic undifferentiated schizophrenia; Restzustand (schizophrenic); Schizophrenic residual state
295.62	Residual Schizophrenia, Chronic State Chronic undifferentiated schizophrenia; Restzustand (schizophrenic); Schizophrenic residual state
295.63	Residual Schizophrenia, Subchronic State With Acute Exacerbation Chronic undifferentiated schizophrenia; Restzustand (schizophrenic); Schizophrenic residual state

295.64	Residual Schizophrenia, Chronic State With Acute Exacerbation Chronic undifferentiated schizophrenia; Restzustand (schizophrenic); Schizophrenic residual state
295.65	Residual Schizophrenia, In Remission Chronic undifferentiated schizophrenia; Restzustand (schizophrenic); Schizophrenic residual state
295.70	Schizoaffective Disorder, Unspecified State Cyclic schizophrenia; Mixed schizophrenic and affective psychosis; Schizo-affective psychosis; Schizophreniform psychosis, affective type
295.71	Schizoaffective Disorder, Subchronic State Cyclic schizophrenia; Mixed schizophrenic and affective psychosis; Schizo-affective psychosis; Schizophreniform psychosis, affective type
295.72	Schizoaffective Disorder, Chronic State Cyclic schizophrenia; Mixed schizophrenic and affective psychosis; Schizo-affective psychosis; Schizophreniform psychosis, affective type
295.73	Schizoaffective Disorder, Subchronic State With Acute Exacerbation Cyclic schizophrenia; Mixed schizophrenic and affective psychosis; Schizo-affective psychosis; Schizophreniform psychosis, affective type
295.74	Schizoaffective Disorder, Chronic State With Acute Exacerbation Cyclic schizophrenia; Mixed schizophrenic and affective psychosis; Schizo-affective psychosis; Schizophreniform psychosis, affective type
295.75	Schizoaffective Disorder, In Remission Cyclic schizophrenia; Mixed schizophrenic and affective psychosis; Schizo-affective psychosis; Schizophreniform psychosis, affective type
295.80	Other Specified Types Of Schizophrenia, Unspecified State Acute (undifferentiated) schizophrenia; Atypical schizophrenia; Cenesthopathic schizophrenia
295.81	Other Specified Types Of Schizophrenia, Subchronic State Acute (undifferentiated) schizophrenia; Atypical schizophrenia; Cenesthopathic schizophrenia
295.82	Other Specified Types Of Schizophrenia, Chronic State Acute (undifferentiated) schizophrenia; Atypical schizophrenia; Cenesthopathic schizophrenia
295.83	Other Specified Types Of Schizophrenia, Subchronic State With Acute Exacerbation Acute (undifferentiated) schizophrenia; Atypical schizophrenia; Cenesthopathic schizophrenia
295.84	Other Specified Types Of Schizophrenia, Chronic State With Acute Exacerbation Acute (undifferentiated) schizophrenia; Atypical schizophrenia; Cenesthopathic schizophrenia

295.85	Other Specified Types Of Schizophrenia, In Remission Acute (undifferentiated) schizophrenia; Atypical schizophrenia; Cenesthopathic schizophrenia
295.90	Unspecified Schizophrenia, Unspecified State Schizophrenia: NOS, mixed NOS, undifferentiated NOS; Schizophrenic reaction NOS; Schizophreniform psychosis NOS
295.91	Unspecified Schizophrenia, Subchronic State Schizophrenia: NOS, mixed NOS, undifferentiated NOS; Schizophrenic reaction NOS; Schizophreniform psychosis NOS
295.92	Unspecified Schizophrenia, Chronic State Schizophrenia: NOS, mixed NOS, undifferentiated NOS; Schizophrenic reaction NOS; Schizophreniform psychosis NOS
295.93	Unspecified Schizophrenia, Subchronic State With Acute Exacerbation Schizophrenia: NOS, mixed NOS, undifferentiated NOS; Schizophrenic reaction NOS; Schizophreniform psychosis NOS
295.94	Unspecified Schizophrenia, Chronic State With Acute Exacerbation Schizophrenia: NOS, mixed NOS, undifferentiated NOS; Schizophrenic reaction NOS; Schizophreniform psychosis NOS
295.95	Unspecified Schizophrenia, In Remission Schizophrenia: NOS, mixed NOS, undifferentiated NOS; Schizophrenic reaction NOS; Schizophreniform psychosis NOS
Episodic Mood Disorders	
296.00	Bipolar I Disorder, Single Manic Episode, Unspecified Degree {Hypomania (mild) NOS} {Hypomanic psychosis} {Mania (monopolar) NOS} {Manic-depressive psychosis or reaction: hypomanic, manic} single episode or unspecified
296.01	Bipolar I Disorder, Single Manic Episode, Mild Degree {Hypomania (mild) NOS} {Hypomanic psychosis} {Mania (monopolar) NOS} {Manic-depressive psychosis or reaction: hypomanic, manic} single episode or unspecified
296.02	Bipolar I Disorder, Single Manic Episode, Moderate Degree {Hypomania (mild) NOS} {Hypomanic psychosis} {Mania (monopolar) NOS} {Manic-depressive psychosis or reaction: hypomanic, manic} single episode or unspecified
296.03	Bipolar I Disorder, Single Manic Episode Severe Degree, Without Mention Of Psychotic Behavior {Hypomania (mild) NOS} {Hypomanic psychosis} {Mania (monopolar) NOS} {Manic-depressive psychosis or reaction: hypomanic, manic} single episode or unspecified

296.04	Bipolar I Disorder, Single Manic Episode, Severe Degree, Specified As With Psychotic Behavior {Hypomania (mild) NOS} {Hypomanic psychosis} {Mania (monopolar) NOS} {Manic-depressive psychosis or reaction: hypomanic, manic} single episode or unspecified
296.05	Bipolar I Disorder, Single Manic Episode, In Partial Or Unspecified Remission {Hypomania (mild) NOS} {Hypomanic psychosis} {Mania (monopolar) NOS} {Manic-depressive psychosis or reaction: hypomanic, manic} single episode or unspecified
296.06	Bipolar I Disorder, Single Manic Episode, In Full Remission {Hypomania (mild) NOS} {Hypomanic psychosis} {Mania (monopolar) NOS} {Manic-depressive psychosis or reaction: hypomanic, manic} single episode or unspecified
296.10	Manic Disorder, Recurrent Episode, Unspecified Degree Any condition classifiable to 296.0, stated to be recurrent
296.11	Manic Disorder, Recurrent Episode, Mild Degree Any condition classifiable to 296.0, stated to be recurrent
296.12	Manic Disorder, Recurrent Episode, Moderate Degree Any condition classifiable to 296.0, stated to be recurrent
296.13	Manic Disorder, Recurrent Episode, Severe Degree, Without Mention Of Psychotic Behavior Any condition classifiable to 296.0, stated to be recurrent
296.14	Manic Disorder, Recurrent Episode, Severe Degree, Specified As With Psychotic Behavior Any condition classifiable to 296.0, stated to be recurrent
296.15	Manic Disorder, Recurrent Episode, In Partial Or Unspecified Remission Any condition classifiable to 296.0, stated to be recurrent
296.16	Manic Disorder, Recurrent Episode, In Full Remission Any condition classifiable to 296.0, stated to be recurrent
296.40	Bipolar I Disorder, Most Recent Episode (Or Current) Manic, Unspecified Degree Bipolar disorder, now manic; Manic-depressive psychosis, circular type but currently manic
296.41	Bipolar I Disorder, Most Recent Episode (Or Current) Manic, Mild Degree Bipolar disorder, now manic; Manic-depressive psychosis, circular type but currently manic
296.42	Bipolar I Disorder, Most Recent Episode (Or Current) Manic, Moderate Degree Bipolar disorder, now manic; Manic-depressive psychosis, circular type but currently manic
296.43	Bipolar I Disorder, Most Recent Episode (Or Current) Manic, Severe Degree, Without Mention Of Psychotic Behavior Bipolar disorder, now manic Manic-depressive psychosis, circular type but currently manic

296.44	Bipolar I Disorder, Most Recent Episode (Or Current) Manic, Severe Degree, Specified As With Psychotic Behavior Bipolar disorder, now manic; Manic-depressive psychosis, circular type but currently manic
296.45	Bipolar I Disorder, Most Recent Episode (Or Current) Manic, In Partial Or Unspecified Remission Bipolar disorder, now manic; Manic-depressive psychosis, circular type but currently manic
296.46	Bipolar I Disorder, Most Recent Episode (Or Current) Manic, In Full Remission Bipolar disorder, now manic Manic-depressive psychosis, circular type but currently manic
296.50	Bipolar I Disorder, Most Recent Episode (Or Current) Depressed, Unspecified Degree Bipolar disorder, now depressed; Manic-depressive psychosis, circular type but currently depressed
296.51	Bipolar I Disorder, Most Recent Episode (Or Current) Depressed, Mild Degree Bipolar disorder, now depressed; Manic-depressive psychosis, circular type but currently depressed
296.52	Bipolar I Disorder, Most Recent Episode (Or Current) Depressed, Moderate Degree Bipolar disorder, now depressed; Manic-depressive psychosis, circular type but currently depressed
296.53	Bipolar I Disorder, Most Recent Episode (Or Current) Depressed, Severe Degree, Without Mention Of Psychotic Behavior Bipolar disorder, now depressed; Manic-depressive psychosis, circular type but currently depressed
296.54	Bipolar I Disorder, Most Recent Episode (Or Current) Depressed, Severe Degree, Specified As With Psychotic Behavior Bipolar disorder, now depressed; Manic-depressive psychosis, circular type but currently depressed
296.55	Bipolar I Disorder, Most Recent Episode (Or Current) Depressed, In Partial Or Unspecified Remission Bipolar disorder, now depressed; Manic-depressive psychosis, circular type but currently depressed
296.56	Bipolar I Disorder, Most Recent Episode (Or Current) Depressed, In Remission Bipolar disorder, now depressed; Manic-depressive psychosis, circular type but currently depressed
296.60	Bipolar I Disorder, Most Recent Episode (Or Current) Mixed, Unspecified Degree Manic-depressive psychosis, circular type, mixed
296.61	Bipolar I Disorder, Most Recent Episode (Or Current) Mixed, Mild Degree Manic-depressive psychosis, circular type, mixed

296.62	Bipolar I Disorder, Most Recent Episode (Or Current) Mixed, Moderate Degree Manic-depressive psychosis, circular type, mixed
296.63	Bipolar I Disorder, Most Recent Episode (Or Current) Mixed, Severe Degree, Without Mention Of Psychotic Behavior Manic-depressive psychosis, circular type, mixed
296.64	Bipolar I Disorder, Most Recent Episode (Or Current) Mixed, Severe Degree, Specified As With Psychotic Behavior Manic-depressive psychosis, circular type, mixed
296.65	Bipolar I Disorder, Most Recent Episode (Or Current) Mixed, In Partial Or Unspecified Remission Manic-depressive psychosis, circular type, mixed
296.66	Bipolar I Disorder, Most Recent Episode (Or Current) Mixed, In Full Remission Manic-depressive psychosis, circular type, mixed
296.7	Bipolar I disorder, most recent episode 9or current0 unspecified
296.80	Bipolar Disorder, Unspecified Bipolar disorder NOS; Manic-depressive: reaction NOS, syndrome NOS
296.81	Atypical Manic Disorder
296.82	Atypical Depressive Disorder
296.89	Other Manic-depressive Psychosis Bipolar II Disorder; Manic-depressive psychosis, mixed type
296.90	Unspecified Episodic Mood Disorder Affective psychosis NOS; Melancholia NOS; Mood disorder NOS
296.99	Other Specified Episodic Mood Disorder Mood swings: brief compensatory, rebound
Delusional disorders	
297.0	Paranoid State, Simple
297.1	Delusional Disorder Chronic paranoid psychosis; Sander's disease; Systematized delusions
297.2	Paraphrenia Involutional paranoid state; Late paraphrenia; Paraphrenia (involutional)
297.3	Shared Psychotic Disorder Folie a deux; Induced psychosis or paranoid disorder
297.8	Other Specified Paranoid States Paranoia querulans; Sensitiver Beziehungswahn
297.9	Unspecified Paranoid State Paranoid: disorder NOS, psychosis NOS, reaction NOS, state NOS
298.0	Depressive Type Psychosis Psychogenic depressive psychosis; Psychotic reactive depression; Reactive depressive psychosis
298.1	Excitative Type Psychosis Acute hysterical psychosis; Psychogenic excitation; Reactive excitation

298.2	Reactive Confusion Psychogenic confusion; Psychogenic twilight state
298.3	Acute Paranoid Reaction Acute psychogenic paranoid psychosis; Bouffee delirante
298.4	Psychogenic Paranoid Psychosis Protracted reactive paranoid psychosis
298.8	Other And Unspecified Reactive Psychosis Brief psychotic disorder; Brief reactive psychosis NOS; Hysterical psychosis; Psychogenic psychosis NOS; Psychogenic stupor
298.9	Unspecified Psychosis Atypical psychosis; Psychosis NOS; Psychotic disorder NOS
301.20	Schizoid Personality Disorder, Unspecified
301.21	Introverted Personality
301.22	Schizotypal Personality Disorder
Autism	
299.00	Autistic Disorder Childhood autism; Infantile psychosis; Kanner's syndrome
299.01	Autistic Disorder, Residual State Childhood autism; Infantile psychosis; Kanner's syndrome
299.10	Childhood Disintegrative Disorder, Current Or Active State Heller's syndrome
299.11	Childhood Disintegrative Disorder, Residual State Heller's syndrome
299.80	Other Specified Pervasive Developmental Disorders, Current Or Active State Atypical childhood psychosis; Borderline psychosis of childhood
299.81	Other Specified Pervasive Developmental Disorders, Residual State Atypical childhood psychosis; Borderline psychosis of childhood
299.90	Unspecified Pervasive developmental disorder, Current Or Active State Child psychosis NOS; Schizophrenia, childhood type NOS; Schizophrenic syndrome of childhood NOS
299.91	Unspecified Pervasive developmental disorder, Residual State Child psychosis NOS; Schizophrenia, childhood type NOS; Schizophrenic syndrome of childhood NOS
Dementias	
290.0	Senile Dementia, Uncomplicated Senile dementia: NOS, simple type
290.10	Presenile Dementia, Uncomplicated Brain syndrome with presenile brain disease; Dementia in: Alzheimer's disease, Jakob-Creutzfeldt disease, Pick's disease of the brain; Presenile dementia: NOS, simple type

290.11	Presenile Dementia, With Delirium Brain syndrome with presenile brain disease; Dementia in: Alzheimer's disease, Jakob-Creutzfeldt disease, Pick's disease of the brain; Presenile dementia with acute confusional state
290.12	Presenile Dementia, With Delusional Features Brain syndrome with presenile brain disease; Dementia in: Alzheimer's disease, Jakob-Creutzfeldt disease, Pick's disease of the brain; Presenile dementia, paranoid type
290.13	Presenile Dementia, With Depressive Features Brain syndrome with presenile brain disease; Dementia in: Alzheimer's disease, Jakob-Creutzfeldt disease, Pick's disease of the brain; Presenile dementia, depressed type
290.20	Senile Dementia With Delusional Features Senile dementia, paranoid type; Senile psychosis NOS
290.21	Senile Dementia With Depressive Features
290.3	Senile Dementia With Delirium Senile dementia with acute confusional state
290.40	Vascular Dementia, Uncomplicated Arteriosclerotic dementia: NOS, simple type; Multi-infarct dementia or psychosis
290.41	Vascular Dementia, With Delirium Arteriosclerotic dementia with acute confusional state; Multi-infarct dementia or psychosis
290.42	Vascular Dementia, With Delusions Arteriosclerotic dementia, paranoid type; Multi-infarct dementia or psychosis
290.43	Vascular Dementia, With Depressed Mood Arteriosclerotic dementia, depressed type; Multi-infarct dementia or psychosis
290.8	Other Specified Senile Psychotic Conditions Presbyophrenic psychosis
290.9	Unspecified Senile Psychotic Condition
Dissociative, Conversion And Factitious Disorders	
300.10	Hysteria, Unspecified
300.11	Conversion Disorder Astasia-abasia, hysterical; Conversion hysteria or reaction; Hysterical: blindness, deafness, paralysis
300.12	Dissociative Amnesia Hysterical amnesia
300.13	Dissociative Fugue Hysterical fugue
300.14	Dissociative Identity Disorder
300.15	Dissociative Disorder Or Reaction, Unspecified
300.16	Factitious Disorder With Predominantly Psychological Signs And Symptoms Compensation neurosis; Ganser's syndrome, hysterical

300.19	Other And Unspecified Factitious Illness Factitious Disorder (with combined psychological and physical signs and symptoms) (with predominantly physical signs and symptoms) NOS
Other	
292.11	Drug-Induced Psychotic Disorder With Delusions Paranoid state induced by drugs
292.12	Drug-Induced Psychotic Disorder With Hallucinations Hallucinatory state induced by drugs
293.81	Psychotic Disorder With Delusions In Conditions Classified Elsewhere Transient organic psychotic condition, paranoid type
293.82	Psychotic Disorder With Hallucinations In Conditions Classified Elsewhere Transient organic psychotic condition, hallucinatory type
307.20	Tic Disorder, Unspecified Tic disorder NOS
307.21	Transient Tic Disorder
307.22	Chronic Motor Or Vocal Tic Disorder
307.23	Tourette's Disorder Motor-verbal tic disorder
313.81	Oppositional Defiant Disorder Of Childhood Or Adolescence
333.4	Huntington's Chorea

*Non preferred Injectable Antipsychotics will be approved after a 2-week trial of ONE preferred Antipsychotic (oral or parenteral) at an appropriate dose. If Invega® Sustenna® is selected as non preferred, approval will be granted if one of the following is true:

- Trial and failure of risperidone; OR
- Patient has hepatic impairment evident by elevated liver enzymes or a diagnosis suggestive of hepatic impairment

**For a diagnosis not specifically mentioned above, an injectable antipsychotic may be approved if the prescriber can provide documented clinical evidence (peer reviewed literature or multiple case studies) supporting the use of the requested medication for the requested indication.

Multiple Therapy Criteria:

Patients who are on more than two Second-Generation Antipsychotic agents will require PA. Approval will be granted for the following reasons:

- A maximum of 2 months to allow patients to taper to dual therapy.
- Additional agents may be added to existing dual therapy after a 2-week trial at the maximum tolerated dose if each agent.

Proposed Quantity Limits:

Drug	Strength	Per Day Count
Abilify®	9.7 mg/1.3 mL	1.3 mL per day
fluphenazine decanoate	25 mg/mL	4 mL per month
haloperidol decanoate / Haldol® Decanoate	50 mg/mL	1 mL per month
	100 mg/mL	2 mL per month
Zyprexa®	10 mg	30 mg per RX
Zyprexa® Relprevv	210 mg	210 mg every 2 weeks
	300 mg	300 mg every 2 weeks
	405 mg	405 mg every 4 weeks
Invega® Sustenna™	39 mg/0.25 mL	0.25 mL per month
	78 mg/0.5 mL	0.5 mL per month
	117 mg/0.75 mL	0.75 mL per month
	156 mg/1 mL	1 mL per month
	234 mg/1.5mL	1.5 mL per month
Risperdal® Consta®	12.5 mg	12.5 mg every 2 weeks
	25 mg	25 mg every 2 weeks
	37.5 mg	37.5 mg every 2 weeks
	50 mg	50 mg every 2 weeks
Geodon®	20 mg	40 mg per RX

Second-Generation Antipsychotic and SSRI Combinations

1. DMS to select preferred agent(s) based on economic evaluation.
2. Require prior authorization and quantity limits for agents in this class.
3. Require prior authorization if this product is being used with more than one other second-generation antipsychotic unless switching agents due to therapeutic failure or the patient is refractory to dual second-generation antipsychotic therapy.
4. Allow continuation of therapy for non preferred single source branded products via a 90 day look back.
5. For any new chemical entity in the Second-Generation Antipsychotic and SSRI Combination class, require a PA until reviewed by the P&T Advisory Committee.

Item	Options for Consideration									
<p align="center"><u>Second-Generation Antipsychotic and SSRI Combinations Clinical Criteria</u></p>	<p>Olanzapine/fluoxetine will be approved if ONE of the following is true:</p> <ul style="list-style-type: none"> • Diagnosis of depressive episodes associated with bipolar disorder after trial and failure of ONE of the following: <ul style="list-style-type: none"> ○ Lithium; OR ○ Lamotrigine; OR ○ Bupropion; OR ○ Paroxetine. • Diagnosis of treatment-resistant depression after trial and failure of one agent from THREE of the following classes of medications: <ul style="list-style-type: none"> ○ SSRI; ○ SNRI; ○ New Generation Antidepressant; ○ Tricyclic Antidepressant; ○ MAOI. <p>**For a diagnosis not specifically mentioned above, olanzapine/fluoxetine may be approved if the prescriber can provide documented clinical evidence (peer reviewed literature or multiple case studies) supporting the use of the requested medication for the requested indication.</p> <p>Multiple Therapy Criteria: Patients who are on more than 2 Second-Generation Antipsychotic agents will require PA. Approval will be granted for the following reasons:</p> <ul style="list-style-type: none"> • A maximum of 2 months to allow patients to taper to dual therapy. • Additional agents may be added to existing dual therapy after a 2-week trial at the maximum tolerated dose of each agent. <p>Proposed Quantity Limits:</p> <table border="1" data-bbox="492 1241 1552 1346"> <thead> <tr> <th>Drug</th> <th>Strength</th> <th>Per Day Count</th> </tr> </thead> <tbody> <tr> <td>Symbyax[®]</td> <td>All Strengths</td> <td>1 per day</td> </tr> <tr> <td>olanzapine/fluoxetine</td> <td>All Strengths</td> <td>1 per day</td> </tr> </tbody> </table>	Drug	Strength	Per Day Count	Symbyax [®]	All Strengths	1 per day	olanzapine/fluoxetine	All Strengths	1 per day
Drug	Strength	Per Day Count								
Symbyax [®]	All Strengths	1 per day								
olanzapine/fluoxetine	All Strengths	1 per day								
<p align="center"><u>First Generation Anticonvulsants</u></p>	<ol style="list-style-type: none"> 1. DMS to select preferred agent (s) based on economic evaluation; however, at least all generic products should be preferred. 2. Agents not selected as preferred will be considered non preferred and require prior authorization. 3. Require therapeutic failure of one preferred agent prior to approval of a non-preferred agent. 4. For any agent not selected as preferred, DMS to allow continuation of therapy if there is a paid claim in the past 90 days. 5. For any new chemical entity in the First Generation Anticonvulsants class, require a PA until reviewed by the P&T Advisory Committee. 									

Item	Options for Consideration
<p align="center"><u>Second Generation Anticonvulsants</u></p>	<ol style="list-style-type: none"> 1. DMS to select preferred agent (s) based on economic evaluation; however, at least five unique chemical entities should be preferred. 2. Agents not selected as preferred will be considered non preferred and require prior authorization. 3. Require therapeutic failure of one preferred agent prior to approval of a non-preferred agent. 4. For any agent not selected as preferred, DMS to allow continuation of therapy if there is a paid claim in the past 90 days. 5. For any new chemical entity in the Second Generation Anticonvulsants class, require a PA until reviewed by the P&T Advisory Committee.
<p><u>Banzel™ Clinical Criteria</u></p>	<p>Banzel™ should be approved if:</p> <ul style="list-style-type: none"> • Diagnosis of Lennox-Gastaut syndrome; OR • Trial and failure of one other anticonvulsant.
<p><u>Lyrica® Clinical Criteria</u></p>	<p>Lyrica® should be approved if any ONE of the following is true:</p> <ul style="list-style-type: none"> • Diabetic Peripheral Neuropathy (DPN); OR • Neuropathic pain associated with spinal cord injury; OR • Postherpetic Neuralgia (PHN) AFTER adequate trial and failure of OR intolerance OR contraindication to at least one of these first-line agents <ul style="list-style-type: none"> ▪ Tricyclic antidepressant (TCAs); or ▪ Anticonvulsant: gabapentin; or ▪ Topical: Lidocaine 5% patch. • Adjunct for partial onset seizure disorder; OR • Fibromyalgia.
<p><u>Sabril® Clinical Criteria</u></p>	<p>Sabril® should be approved if:</p> <ul style="list-style-type: none"> • Diagnosis of infantile spasms; OR • Trial and failure of one other anticonvulsant.
<p align="center"><u>Anticonvulsants, Carbamazepine Derivatives</u></p>	<ol style="list-style-type: none"> 1. DMS to select preferred agent (s) based on economic evaluation; however, at least two unique chemical entities should be preferred. 2. Agents not selected as preferred will be considered non preferred and require prior authorization. 3. Require therapeutic failure of one preferred agent prior to approval of a non-preferred agent. 4. For any agent not selected as preferred, DMS to allow continuation of therapy if there is a paid claim in the past 90 days. 5. For any new chemical entity in the Anticonvulsants, Carbamazepine Derivatives class, require a PA until reviewed by the P&T Advisory Committee.

Item	Options for Consideration																				
<p><u>Stimulants and Related Agents</u></p>	<ol style="list-style-type: none"> 1. DMS to select preferred agent(s) based on economic evaluation; however, at least one short-acting, one intermediate-acting and one long-acting formulation of methylphenidate and dextroamphetamine as well as atomoxetine should be preferred. 2. Agents not selected as preferred will be considered non preferred and require prior approval. 3. Require appropriate ICD-9 on all prescriptions for agents within this class. 4. Continue to require prior authorization for modafinil and armodafinil to ensure utilization in FDA-approved indications only. 5. Place quantity limits on all agents based on the American Academy of Child and Adolescent Psychiatry and FDA-approved maximum recommended dose. 6. Allow only one agent at a time for an extended release product and one agent at a time for an immediate release product unless switching agents due to therapeutic failure. 7. Allow continuation of therapy for non preferred single-source branded products via a 90 day look back. 8. For any new chemical entity in the Stimulants and Related Agents class, require a PA until reviewed by the P&T Advisory Committee. 																				
<p><u>Stimulants and Related Agents Clinical Criteria</u></p>	<p>Diagnosis to Approve via an ICD-9 Override:</p> <table border="1" data-bbox="448 894 1552 1383"> <thead> <tr> <th data-bbox="448 894 1008 928">Diagnosis</th> <th data-bbox="1008 894 1552 928">ICD-9</th> </tr> </thead> <tbody> <tr> <td data-bbox="448 928 1008 1104" rowspan="5">Attention Deficit/Hyperactivity Disorder (ADHD)</td> <td data-bbox="1008 928 1552 961">314.1</td> </tr> <tr> <td data-bbox="1008 961 1552 995">314.01</td> </tr> <tr> <td data-bbox="1008 995 1552 1029">314.2</td> </tr> <tr> <td data-bbox="1008 1029 1552 1062">314.8</td> </tr> <tr> <td data-bbox="1008 1062 1552 1096">314.9</td> </tr> <tr> <td data-bbox="448 1104 1008 1138">Attention Deficit Disorder (ADD)</td> <td data-bbox="1008 1104 1552 1138">314.00</td> </tr> <tr> <td data-bbox="448 1138 1008 1245" rowspan="3">Narcolepsy</td> <td data-bbox="1008 1138 1552 1171">347.00</td> </tr> <tr> <td data-bbox="1008 1171 1552 1205">347.01</td> </tr> <tr> <td data-bbox="1008 1205 1552 1239">347.11</td> </tr> <tr> <td data-bbox="448 1245 1008 1352" rowspan="3">Sleep apnea/hypoapnea syndrome</td> <td data-bbox="1008 1245 1552 1278">780.57</td> </tr> <tr> <td data-bbox="1008 1278 1552 1312">780.51</td> </tr> <tr> <td data-bbox="1008 1312 1552 1346">780.53</td> </tr> <tr> <td data-bbox="448 1352 1008 1383">Shift work sleep disorder</td> <td data-bbox="1008 1352 1552 1383">307.45</td> </tr> </tbody> </table> <p data-bbox="448 1388 1490 1455">**Agents may be approved for other diagnosis via the prior authorization process based on a review of the current literature by a clinical pharmacist.</p> <p data-bbox="448 1486 1481 1554">Daytrana™, Methylin® Solution, Methylin® Chewable Tabs, or Procentra™ will be approved if either of the following criteria is met:</p> <ul style="list-style-type: none"> • Trial and failure of two preferred products, one of which must be the same chemical as the requested medication; OR • Inability to swallow/tolerate PO/whole tablets/capsules <ul style="list-style-type: none"> ○ For Daytrana™, inability to swallow/tolerate PO medications; OR ○ For Methylin® Solution, Methylin® Chewable Tabs, or Procentra™, inability to swallow tablets or capsules whole. 	Diagnosis	ICD-9	Attention Deficit/Hyperactivity Disorder (ADHD)	314.1	314.01	314.2	314.8	314.9	Attention Deficit Disorder (ADD)	314.00	Narcolepsy	347.00	347.01	347.11	Sleep apnea/hypoapnea syndrome	780.57	780.51	780.53	Shift work sleep disorder	307.45
Diagnosis	ICD-9																				
Attention Deficit/Hyperactivity Disorder (ADHD)	314.1																				
	314.01																				
	314.2																				
	314.8																				
	314.9																				
Attention Deficit Disorder (ADD)	314.00																				
Narcolepsy	347.00																				
	347.01																				
	347.11																				
Sleep apnea/hypoapnea syndrome	780.57																				
	780.51																				
	780.53																				
Shift work sleep disorder	307.45																				

	<p><u>Therapeutic Duplication</u> Prior authorization will be required for more than one long-acting (Adderall XR[®], Concerta[®], Daytrana[™], Dexedrine[®], dextroamphetamine ER, Metadate CD[®], Metadate ER[®], Focalin XR[™], Methylin ER[®], methylphenidate ER, methylphenidate ER OROS, methylphenidate SR, mixed amphetamine salt ER, Ritalin LA[®], Ritalin SR[®], Strattera[®], Vyvanse[™]), or more than one short-acting (Adderall[®], Desoxyn[®], dexmethylphenidate IR, dextroamphetamine IR, DextroStat[®], Focalin[™], methamphetamine, Methylin[®], methylphenidate IR, mixed amphetamine salt IR, Procentra[™], Ritalin[®]) stimulant at a time.</p>										
<p><u>Strattera[®] Clinical Criteria</u></p>	<p>Strattera[®] (atomoxetine) will be approved if both of the following criteria are met:</p> <ul style="list-style-type: none"> • Diagnosis of: <table border="1" data-bbox="448 594 1552 835"> <thead> <tr> <th><u>Diagnosis</u></th> <th><u>ICD-9</u></th> </tr> </thead> <tbody> <tr> <td rowspan="5">Attention Deficit/Hyperreactivity Disorder (ADHD)</td> <td>314.1</td> </tr> <tr> <td>314.01</td> </tr> <tr> <td>314.2</td> </tr> <tr> <td>314.8</td> </tr> <tr> <td>314.9</td> </tr> <tr> <td>Attention Deficit Disorder (ADD)</td> <td>314.00</td> </tr> </tbody> </table> <p>AND;</p> <ul style="list-style-type: none"> • Any one of the following criteria: <ul style="list-style-type: none"> ○ Trial and failure of one preferred stimulant and related agent in the past 90 days; OR ○ History of substance abuse or diversion on the part of the patient or caregiver; OR ○ History of stimulant-induced weight loss after trial of two stimulants; OR ○ History of tic disorder, including Tourette's; OR ○ Co-morbid mood or anxiety disorder. 	<u>Diagnosis</u>	<u>ICD-9</u>	Attention Deficit/Hyperreactivity Disorder (ADHD)	314.1	314.01	314.2	314.8	314.9	Attention Deficit Disorder (ADD)	314.00
<u>Diagnosis</u>	<u>ICD-9</u>										
Attention Deficit/Hyperreactivity Disorder (ADHD)	314.1										
	314.01										
	314.2										
	314.8										
	314.9										
Attention Deficit Disorder (ADD)	314.00										
<p><u>Provigil[®]/Nuvigil[®] Clinical Criteria</u></p>	<p>Provigil[®] (modafinil) / Nuvigil[®] (armodafinil) will be approved if both of the following criteria are met:</p> <ul style="list-style-type: none"> • One of the following approvable diagnosis (via ICD-9 override): <table border="1" data-bbox="448 1310 1552 1556"> <tbody> <tr> <td rowspan="3">Narcolepsy</td> <td>347.00</td> </tr> <tr> <td>347.01</td> </tr> <tr> <td>347.11</td> </tr> <tr> <td rowspan="3">Sleep apnea/hypoapnea syndrome</td> <td>780.57</td> </tr> <tr> <td>780.51</td> </tr> <tr> <td>780.53</td> </tr> <tr> <td>Shift work sleep disorder</td> <td>307.45</td> </tr> </tbody> </table> • For Nuvigil[®] (armodafinil) ONLY, trial and failure of Provigil[®] (modafinil) 	Narcolepsy	347.00	347.01	347.11	Sleep apnea/hypoapnea syndrome	780.57	780.51	780.53	Shift work sleep disorder	307.45
Narcolepsy	347.00										
	347.01										
	347.11										
Sleep apnea/hypoapnea syndrome	780.57										
	780.51										
	780.53										
Shift work sleep disorder	307.45										
<p><u>SSRIs</u></p>	<ol style="list-style-type: none"> 1. DMS to select preferred agent(s) based upon economic evaluation; however, at least three unique chemical entities should be preferred. 2. Agents not selected as preferred will be considered non-preferred and will require Prior Authorization. 3. Any new chemical entity in the SSRI class should require a PA until reviewed by the P&T Advisory Committee. 										

Item	Options for Consideration
<u>SNRIs</u>	<ol style="list-style-type: none"> 1. DMS to select preferred agent(s) based upon economic evaluation; however, at least one long acting SNRI should be preferred. 2. Agents not selected as preferred will be considered non-preferred and will require Prior Authorization. 3. Clinical criteria should be placed on milnacipran to ensure it is being used for its FDA-approved indication only. 4. Any new chemical entity in the SNRI class should require a PA until reviewed by the P&T Advisory Committee.
<u>Cymbalta® Clinical Criteria</u>	<p>Cymbalta® should be authorized for the following diagnoses:</p> <ul style="list-style-type: none"> • Depression/Major Depressive Disorder/Generalized Anxiety Disorder/Social Anxiety Disorder/Panic Disorder: Approval after trial and failure or intolerance or contraindication to one preferred SNRI. • Diabetic peripheral neuropathic pain • Fibromyalgia • Chronic musculoskeletal pain: Approval after trial and failure of or intolerance or contraindication to one NSAID.
<u>New Generation Antidepressants</u>	<ol style="list-style-type: none"> 1. DMS to select preferred agent(s) based upon economic evaluation; however, at least bupropion and trazodone should be preferred. 2. Agents not selected as preferred will be considered non-preferred and will require Prior Authorization. 3. Any new chemical entity in the New Generation Antidepressants class should require a PA until reviewed by the P&T Advisory Committee.
<u>Tricyclic Antidepressants</u>	<ol style="list-style-type: none"> 1. DMS to select preferred agent(s) based upon economic evaluation; however, at least four unique chemical entities should be preferred. 2. Agents not selected as preferred will be considered non-preferred and will require Prior Authorization. 3. Any new chemical entity in the Tricyclic Antidepressants class should require a PA until reviewed by the P&T Advisory Committee.
<u>MAOIs</u>	<ol style="list-style-type: none"> 1. DMS to select preferred agent(s) based upon economic evaluation. 2. Agents not selected as preferred will be considered non-preferred and will require Prior Authorization. 3. Any new chemical entity in the Monoamine Oxidase Inhibitors class should require a PA until reviewed by the P&T Advisory Committee.